CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 110 enrolled
Drug / intervention
Flaxseed +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00781950
NCT00781950Phase 3Completed
CompareCT.gov

A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease

Dr. Grant Pierce·interventional·Posted Oct 29, 2008·Updated Dec 12, 2016

In Brief

A Phase 3 clinical trial evaluating Flaxseed and Placebo for Peripheral Arterial Disease. Completed, enrolled 110 participants.

Detailed Summary

This Clinical Trial is being conducted to study how patients with peripheral arterial disease (a condition in which the blood vessels of the extremities are affected) respond to a dietary regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of dietary flaxseed on exercise tolerance will be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 29, 2008
Enrollment StartOct 1, 2008
Primary CompletionMar 1, 2011
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.7 years ago

Interventions

Flaxseeddietary

30 grams of milled flaxseed per day in food products or on its own.

Placebodietary

Wheat and Mixed Dietary Oils